These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30542179)

  • 1. Access and affordability for all.
    Sherman M
    Nature; 2018 Dec; 564(7735):S23. PubMed ID: 30542179
    [No Abstract]   [Full Text] [Related]  

  • 2. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.
    Kesselheim AS; Avorn J
    JAMA; 2016 Dec; 316(22):2357-2358. PubMed ID: 27775756
    [No Abstract]   [Full Text] [Related]  

  • 3. Muscular dystrophy drug looks set for commercial success despite clinical doubts.
    Dyer O
    BMJ; 2016 Oct; 355():i5346. PubMed ID: 27698204
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluating a Stone of Hope: ICER's 2019 Review of Treatments for Duchenne Muscular Dystrophy.
    Brandsema JF
    J Manag Care Spec Pharm; 2020 Apr; 26(4):366-368. PubMed ID: 32223600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.
    Stein CA
    Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
    Aartsma-Rus A; Krieg AM
    Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755
    [No Abstract]   [Full Text] [Related]  

  • 7. [Not Available].
    Kaplan JC
    Med Sci (Paris); 2016 Nov; 32 Hors série n°2():57-59. PubMed ID: 27869079
    [No Abstract]   [Full Text] [Related]  

  • 8. Railroading at the FDA.
    Nat Med; 2016 Nov; 22(11):1193. PubMed ID: 27824816
    [No Abstract]   [Full Text] [Related]  

  • 9. Railroading at the FDA.
    Nat Biotechnol; 2016 Nov; 34(11):1078. PubMed ID: 27824847
    [No Abstract]   [Full Text] [Related]  

  • 10. First Drug Approved for Duchenne Muscular Dystrophy.
    Aschenbrenner DS
    Am J Nurs; 2017 Jan; 117(1):23. PubMed ID: 28030401
    [No Abstract]   [Full Text] [Related]  

  • 11. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe.
    Aartsma-Rus A; Goemans N
    Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patients organizations and new drug approval in the US. Eteplirsen and Duchenne muscular dystrophy case].
    Dal-Ré R; Lopez de Munain A; Ayuso C
    Rev Neurol; 2017 Oct; 65(8):373-380. PubMed ID: 28990648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duchenne muscular dystrophy drugs face tough path to approval.
    Hodgkinson L; Sorbera L; Graul AI
    Drugs Today (Barc); 2016 Mar; 52(3):199-202. PubMed ID: 27186594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic therapies for inherited neuromuscular disorders.
    Scoto M; Finkel R; Mercuri E; Muntoni F
    Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient need versus evidence: a balancing act.
    The Lancet
    Lancet; 2016 Oct; 388(10052):1350. PubMed ID: 27707475
    [No Abstract]   [Full Text] [Related]  

  • 17. Eteplirsen in the treatment of Duchenne muscular dystrophy.
    Lim KR; Maruyama R; Yokota T
    Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.
    Aartsma-Rus A; Straub V; Hemmings R; Haas M; Schlosser-Weber G; Stoyanova-Beninska V; Mercuri E; Muntoni F; Sepodes B; Vroom E; Balabanov P
    Nucleic Acid Ther; 2017 Oct; 27(5):251-259. PubMed ID: 28796573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health, Wealth, and the 21st Century Cures Act.
    Lo AW; Philipson TJ; von Eschenbach AC
    JAMA Oncol; 2016 Jan; 2(1):17-8. PubMed ID: 26513279
    [No Abstract]   [Full Text] [Related]  

  • 20. Duchenne drug clings on for FDA nod.
    Nat Biotechnol; 2017 Nov; 35(11):999. PubMed ID: 29121019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.